Phase 2 CAR-T study reports significant remission rates at 15-month follow up
(PHYSorg.com Medicine & Health)

A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment with axi-cel (marketed as Yescarta).